Stock Events

Stock Events

Kiniksa Pharmaceuticals International. 

$79.28
34
+$0.65+0.83% Tuesday 20:00
-$0.14-0.18%Tuesday 23:30After hours

Statistics

Day High
79.32
Day Low
79.16
52W High
82.94
52W Low
33.45
Volume
13,440
Avg. Volume
-
Mkt Cap
6.19B
P/E Ratio
66.97
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.12
0.04
0.21
0.37
Expected EPS
0.369855
Actual EPS
N/A

Financials

8.71%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
677.56MRevenue
59.01MNet Income

Analyst Ratings

91.29Average Price Target
The highest estimate is 107.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KNSA. It's not an investment recommendation.
Tesla
9
TSLA
NVIDIA
9
NVDA
Microsoft
6
MSFT
Palantir Technologies
6
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on treatments for inflammatory diseases, a key area for Kiniksa.
AMGEN
AMGN
Mkt Cap233.78B
Amgen operates in similar therapeutic areas as Kiniksa, including inflammation and autoimmune diseases, making them direct competitors.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie offers products in immunology and oncology, overlapping with Kiniksa's focus on autoimmune diseases.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a strong presence in the treatment of inflammatory and respiratory diseases, competing with Kiniksa's product offerings.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a diverse portfolio that includes treatments for immune-mediated diseases, directly competing with Kiniksa.
Novartis
NVS
Mkt Cap292.35B
Novartis AG focuses on areas like immunology and dermatology, which are key therapeutic areas for Kiniksa, making them competitors.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad range of products in inflammation and immunology, competing with Kiniksa in the biopharmaceutical market.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the immunology space, overlapping with Kiniksa's interests.
Merck
MRK
Mkt Cap366B
Merck & Co. has initiatives in immunotherapy and inflammatory diseases, areas where Kiniksa is also aiming to make an impact.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a strong focus on respiratory and autoimmune diseases, competing with Kiniksa in developing treatments for similar conditions.

About

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Show more...
CEO
Sanj K. Patel
Employees
366
Country
United Kingdom
ISIN
GB00BRXB0C07

Listings

XNAS
US
KNSA
MX
MX
KNSAN.MX
BOATS
BOATS
KNSA.BOATS

0 Comments

Share your thoughts

FAQ

What is Kiniksa Pharmaceuticals International. stock price today?▼
The current price of KNSA is $79.28 USD — it has increased by +0.83% in the past 24 hours. Watch Kiniksa Pharmaceuticals International. stock price performance more closely on the chart.
What is Kiniksa Pharmaceuticals International. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Kiniksa Pharmaceuticals International. stocks are traded under the ticker KNSA.
Is Kiniksa Pharmaceuticals International. stock price growing?▼
KNSA stock has risen by +0.76% compared to the previous week, the month change is a +6.65% rise, over the last year Kiniksa Pharmaceuticals International. has showed a +131.27% increase.
What is Kiniksa Pharmaceuticals International. market cap?▼
Today Kiniksa Pharmaceuticals International. has the market capitalization of 6.19B
When is the next Kiniksa Pharmaceuticals International. earnings date?▼
Kiniksa Pharmaceuticals International. is going to release the next earnings report on November 03, 2026.
What were Kiniksa Pharmaceuticals International. earnings last quarter?▼
KNSA earnings for the last quarter are 0.3 USD per share, whereas the estimation was 0.3 USD resulting in a +0.18% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kiniksa Pharmaceuticals International. revenue for the last year?▼
Kiniksa Pharmaceuticals International. revenue for the last year amounts to 677.56M USD.
What is Kiniksa Pharmaceuticals International. net income for the last year?▼
KNSA net income for the last year is 59.01M USD.
How many employees does Kiniksa Pharmaceuticals International. have?▼
As of September 02, 2026, the company has 366 employees.
In which sector is Kiniksa Pharmaceuticals International. located?▼
Kiniksa Pharmaceuticals International. operates in the Health & Wellness sector.
When did Kiniksa Pharmaceuticals International. complete a stock split?▼
Kiniksa Pharmaceuticals International. has not had any recent stock splits.
Where is Kiniksa Pharmaceuticals International. headquartered?▼
Kiniksa Pharmaceuticals International. is headquartered in LONDON, United Kingdom.